Glenmark, Cediprof partner to distribute generic Adderall

Glenmark and Cediprof have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed salts of a single entity amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, which is the generic version of Teva Women’s Health’s Adderall.

Glenmark said it expects to commence distribution of the product during the second half of 2023. This product has been on FDA's shortage list.

Commenting on the launch, Brendan O'Grady, CEO of Glenmark global formulations business, said, "Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed salts of a single entity amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to alleviate the shortage this country is facing by partnering with Cediprof and Neol."

[Read more: FDA gives Glenmark 2nd tentative nod for generic Onglyza]

Adderall tablets have a market value of approximately $389.8 million, for the 12-month period ending January 2023, according to IQVIA.